Education
About Us
Working with TipRanks
Follow Us
Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
Total Valuation
Artelo Biosciences has a market cap or net worth of $6.87M. The enterprise value is -$3.11M.
Market Cap$6.87M
Enterprise Value-$3.11M
Share Statistics
Artelo Biosciences has 683,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding683,510
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Artelo Biosciences’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -51.75%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-51.75%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.68M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Artelo Biosciences is -0.83. Artelo Biosciences’s PEG ratio is ―.
PE Ratio-0.83
PS Ratio0.00
PB Ratio0.17
Price to Fair Value0.42
Price to FCF-0.46
Price to Operating Cash Flow-0.40
PEG Ratio―
Income Statement
In the last 12 months, Artelo Biosciences had revenue of 0.00 and earned -10.08M in profits. Earnings per share was -3.49.
Revenue0.00
Gross Profit0.00
Operating Income-10.29M
Pretax Income-10.08M
Net Income-10.08M
EBITDA-10.29M
Earnings Per Share (EPS)-3.49
Cash Flow
In the last 12 months, operating cash flow was -7.80M and capital expenditures 0.00, giving a free cash flow of -7.80M billion.
Operating Cash Flow-7.80M
Free Cash Flow-7.80M
Free Cash Flow per Share-11.41
Dividends & Yields
Artelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change80.13%
50-Day Moving Average6.74
200-Day Moving Average6.62
Relative Strength Index (RSI)70.59
Average Volume (3m)950.12K
Important Dates
Artelo Biosciences upcoming earnings date is Aug 6, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Artelo Biosciences as a current ratio of 18.36, with Debt / Equity ratio of 0.32%
Current Ratio18.36
Quick Ratio18.36
Debt to Market Cap<0.01
Net Debt to EBITDA0.66
Interest Coverage Ratio-2.06K
Taxes
In the past 12 months, Artelo Biosciences has paid -209.00K in taxes.
Income Tax-209.00K
Effective Tax Rate0.02
Enterprise Valuation
Artelo Biosciences EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.17.
EV to Sales0.00
EV to EBITDA-0.13
EV to Free Cash Flow-0.17
EV to Operating Cash Flow-0.17
Balance Sheet
Artelo Biosciences has $13.99M in cash and marketable securities with $40.00K in debt, giving a net cash position of -$13.95M billion.
Cash & Marketable Securities$13.99M
Total Debt$40.00K
Net Cash-$13.95M
Net Cash Per Share-$20.41
Tangible Book Value Per Share$6.13
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Artelo Biosciences is $5.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$5.00
Price Target Upside-65.08% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast14.28%